Biogen: Eisai to Request Reconsideration of Decision Within 90 Days to Make Lecanemab Available for Eligible People Living With Early Ad in Australia
渤健公司:Eisai將在90天內請求重新考慮決定,使Lecanemab對澳洲早期癡呆症患者可用
Biogen: Eisai to Request Reconsideration of Decision Within 90 Days to Make Lecanemab Available for Eligible People Living With Early Ad in Australia
渤健公司:Eisai將在90天內請求重新考慮決定,使Lecanemab對澳洲早期癡呆症患者可用
譯文內容由第三人軟體翻譯。